Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
AstraZeneca
Age
Any age
Sex
FEMALE
Healthy volunteers
Not accepted
You may be eligible if
Postmenopausal woman with early breast cancer who are prescribed with anastrozole as adjuvant endocrine therapy under the routine clinical practice.
Histologically or cytologically proven to be HR+(ER or PR +)
No other concomitant endocrine therapy such as estrogen therapy or selective estrogen receptor modulators
Provision of written informed consent
You may not be if
Recurrence of breast cancer
Known hypersensitivity to anastrozole or to any of its excipients
Any severe concomitant condition which makes it undesirable for the patient to participate in the trial or which would jeopardize adherence with the trial protocol: Amenorrhea\<12 months and a intact uterus; Previous inclusion in the present study; Participation in a other clinical study during the last 30 days·
Women who does not agreed to participate the program
Clareo Health | An Observational Study of Adherence to Anastrozole in Early Breast Cancer Treatment
